KIAA1429‑mediated ZFPM2‑AS1 m<sup>6</sup>A modification promotes the proliferation, migration and invasion of osteosarcoma cells

Zhang,Yuanzhuang; Bao,Yuxin; Zhai,Hanjie; Li,Chenghao; Shi,Hongchao; Gong,Keyang; Bao,Xiaohe

doi:10.3892/ol.2025.15199

KIAA1429‑mediated ZFPM2‑AS1 m⁶A modification promotes the proliferation, migration and invasion of osteosarcoma cells

Authors:
- Yuanzhuang Zhang
- Yuxin Bao
- Hanjie Zhai
- Chenghao Li
- Hongchao Shi
- Keyang Gong
- Xiaohe Bao
View Affiliations

Affiliations: Fourth Department of Orthopedic Surgery, Central Hospital Affiliated to Shenyang Medical College, Shenyang, Liaoning 110024, P.R. China, School of Basic Medicine, Shenyang Medical College, Shenyang, Liaoning 110000, P.R. China
Published online on: July 21, 2025 https://doi.org/10.3892/ol.2025.15199
Article Number: 453
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most prevalent malignant bone tumor in pediatric and adolescent populations. N⁶‑methyladenosine (m⁶A) is a post‑transcriptional modification of RNA, and the most prevalent internal chemical modification of mRNA. KIAA1429, also known as virus‑like m6A methyltransferase‑associated, is a key component of the m6A methyltransferase complex, and the largest protein within this complex. Long non‑coding RNAs (lncRNAs) are a class of transcripts >200 nucleotides in length that are able to regulate gene expression. Friend of GATA family member 2‑antisense 1 (ZFPM2‑AS1) is a lncRNA that has been observed to exhibit aberrantly elevated expression in gastric cancer. The present study aimed to explore the expression levels of KIAA1429 and ZFPM2‑AS1 in osteosarcoma tissues and 143B and MG63 osteosarcoma cell lines. The results of bioinformatics analysis, reverse transcription‑quantitative PCR (qPCR) and western blotting revealed that the expression of KIAA1429 and ZFPM2‑AS1 in osteosarcoma tissues and cell lines was upregulated compared with that in the corresponding normal tissues or cells. The association between KIAA1429‑mediated m⁶A modifications and ZFPM2‑AS1 stability in osteosarcoma cells was confirmed using m⁶A‑methylated RNA immunoprecipitation‑qPCR and actinomycin D assays. In addition, in Cell Counting Kit‑8 and Transwell assays KIAA1429 overexpression promoted the proliferation, invasion and migration of 143B and MG63 osteosarcoma cells, and these promotive effects were attenuated by ZFPM2‑AS1 knockdown. These findings suggest a potential novel approach for molecular therapy in the treatment of osteosarcoma.

View Figures

View References

1	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
2	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
3	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cai Y, Feng R, Lu T, Chen X, Zhou X and Wang X: Novel insights into the m(6)A-RNA methyltransferase METTL3 in cancer. Biomark Res. 9:272021. View Article : Google Scholar : PubMed/NCBI
5	Chen D, Gu X, Nurzat Y, Xu L, Li X, Wu L, Jiao H, Gao P, Zhu X, Yan D, et al: Writers, readers, and erasers RNA modifications and drug resistance in cancer. Mol Cancer. 23:1782024. View Article : Google Scholar : PubMed/NCBI
6	Wang J, Xiu M, Wang J, Gao Y and Li Y: METTL16-SENP3-LTF axis confers ferroptosis resistance and facilitates tumorigenesis in hepatocellular carcinoma. J Hematol Oncol. 17:782024. View Article : Google Scholar : PubMed/NCBI
7	Yu Y, Yang YL, Chen XY, Chen ZY, Zhu JS and Zhang J: Helicobacter pylori-enhanced hnRNPA2B1 coordinates with PABPC1 to promote Non-m(6)A translation and gastric cancer progression. Adv Sci (Weinh). 11:e23097122024. View Article : Google Scholar : PubMed/NCBI
8	Mao L, Wang L, Lyu Y, Zhuang Q, Li Z, Zhang J, Gu Z, Lu S, Wang X, Guan Y, et al: Branch chain amino acid metabolism promotes brain metastasis of NSCLC through EMT occurrence by regulating ALKBH5 activity. Int J Biol Sci. 20:3285–3301. 2024. View Article : Google Scholar : PubMed/NCBI
9	Guo X, Qiu W, Li B, Qi Y, Wang S, Zhao R, Cheng B, Han X, Du H, Pan Z, et al: Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation. Clin Cancer Res. 30:1160–1174. 2024. View Article : Google Scholar : PubMed/NCBI
10	Wei X, Feng J, Chen L, Zhang C, Liu Y, Zhang Y, Xu Y, Zhang J, Wang J, Yang H, et al: METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Lett. August 29–2024.(Ebup ahead of print).
11	Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N, Carl SH, Masiello I, Hares T, Villaseñor R, Hess D, et al: Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev. 32:415–429. 2018. View Article : Google Scholar : PubMed/NCBI
12	Zhu W, Wang JZ, Wei JF and Lu C: Role of m6A methyltransferase component VIRMA in multiple human cancers (Review). Cancer Cell Int. 21:1722021. View Article : Google Scholar : PubMed/NCBI
13	Chen X, Lu T, Cai Y, Han Y, Ding M, Chu Y, Zhou X and Wang X: KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway. Cell Mol Biol Lett. 28:322023. View Article : Google Scholar : PubMed/NCBI
14	Luo J, Wang X, Chen Z, Zhou H and Xiao Y: The role and mechanism of JAK2/STAT3 signaling pathway regulated by m6A methyltransferase KIAA1429 in osteosarcoma. J Bone Oncol. 39:1004712023. View Article : Google Scholar : PubMed/NCBI
15	Goodall GJ and Wickramasinghe VO: RNA in cancer. Nat Rev Cancer. 21:22–36. 2021. View Article : Google Scholar : PubMed/NCBI
16	Fang Y and Fullwood MJ: Roles, functions, and mechanisms of long Non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 14:42–54. 2016. View Article : Google Scholar : PubMed/NCBI
17	Luongo M, Laurenziello P, Cesta G, Bochicchio AM, Omer LC, Falco G, Milone MR, Cibarelli F, Russi S and Laurino S: The molecular conversations of sarcomas: exosomal non-coding RNAs in tumor's biology and their translational prospects. Mol Cancer. 23:1722024. View Article : Google Scholar : PubMed/NCBI
18	Shaath H, Vishnubalaji R, Elango R, Kardousha A, Islam Z, Qureshi R, Alam T, Kolatkar PR and Alajez NM: Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches. Semin Cancer Biol. 86((Pt 3)): 325–345. 2022. View Article : Google Scholar : PubMed/NCBI
19	Shi Q, Chu Q, Zeng Y, Yuan X, Wang J, Zhang Y, Xue C and Li L: Non-coding RNA methylation modifications in hepatocellular carcinoma: Interactions and potential implications. Cell Commun Signal. 21:3592023. View Article : Google Scholar : PubMed/NCBI
20	Xu D, Wang Z and Li F: KIAA1429 Induces m6A Modification of LINC01106 to enhance the malignancy of lung adenocarcinoma cells via the JAK/STAT3 pathway. Crit Rev Immunol. 44:49–61. 2024. View Article : Google Scholar : PubMed/NCBI
21	Han S, Cao D, Sha J, Zhu X and Chen D: LncRNA ZFPM2-AS1 promotes lung adenocarcinoma progression by interacting with UPF1 to destabilize ZFPM2. Mol Oncol. 14:1074–1088. 2020. View Article : Google Scholar : PubMed/NCBI
22	Sun G and Wu C: ZFPM2-AS1 facilitates cell growth in esophageal squamous cell carcinoma via up-regulating TRAF4. Biosci Rep. 40:BSR201943522020. View Article : Google Scholar : PubMed/NCBI
23	Ren R, Du Y, Niu X and Zang R: ZFPM2-AS1 transcriptionally mediated by STAT1 regulates thyroid cancer cell growth, migration and invasion via miR-515-5p/TUSC3. J Cancer. 12:3393–3406. 2021. View Article : Google Scholar : PubMed/NCBI
24	Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and Varambally S: UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
25	Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47((W1)): W556–W560. 2019. View Article : Google Scholar : PubMed/NCBI
26	Zhou Y, Zeng P, Li YH, Zhang Z and Cui Q: SRAMP: Prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 44:e912016. View Article : Google Scholar : PubMed/NCBI
27	Ren S, Zhang Y, Yang X, Li X, Zheng Y, Liu Y and Zhang X: N6-methyladenine-induced LINC00667 promoted breast cancer progression through m6A/KIAA1429 positive feedback loop. Bioengineered. 13:13462–13473. 2022. View Article : Google Scholar : PubMed/NCBI
28	Yang D, Chang S, Li F, Ma M, Yang J, Lv X, Huangfu L and Jia C: m(6) A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1. IUBMB Life. 73:1325–1333. 2021. View Article : Google Scholar : PubMed/NCBI
29	Lu D and Chen A: lncRNA POU6F2-AS1 regulated by KIAA1429 contributes to colorectal cancer progression in an m(6)A modification manner. Mol Biotechnol. 67:115–122. 2025. View Article : Google Scholar : PubMed/NCBI
30	Kong F, Deng X, Kong X, Du Y, Li L, Zhu H, Wang Y, Xie D, Guha S, Li Z, et al: ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 37:5982–5996. 2018. View Article : Google Scholar : PubMed/NCBI
31	Xiao M, Liang Z and Yin Z: Long non-coding RNA ZFPM2-AS1 promotes colorectal cancer progression by sponging miR-137 to regulate TRIM24. Mol Med Rep. 23:982021. View Article : Google Scholar : PubMed/NCBI
32	Xue M, Tao W, Yu S, Yan Z, Peng Q, Jiang F and Gao X: lncRNA ZFPM2-AS1 promotes proliferation via miR-18b-5p/VMA21 axis in lung adenocarcinoma. J Cell Biochem. 121:313–321. 2020. View Article : Google Scholar : PubMed/NCBI
33	Tan F: ZFPM2-AS1: An oncogenic long non-coding RNA in multiple cancer types. Mini Rev Med Chem. 23:88–98. 2023. View Article : Google Scholar : PubMed/NCBI
34	Zhang Y, Xu Y, Bao Y, Luo Y, Qiu G, He M, Lu J, Xu J, Chen B and Wang Y: N6-methyladenosine (m6A) modification in osteosarcoma: expression, function and interaction with noncoding RNAs-an updated review. Epigenetics. 18:22602132023. View Article : Google Scholar : PubMed/NCBI
35	Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK and Kim YK: Endoribonucleolytic cleavage of m(6)A-Containing RNAs by RNase P/MRP complex. Mol Cell. 74:494–507.e8. 2019. View Article : Google Scholar : PubMed/NCBI
36	Cheng Y, Xie W, Pickering BF, Chu KL, Savino AM, Yang X, Luo H, Nguyen DT, Mo S, Barin E, et al: N(6)-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation. Cancer Cell. 39:958–972.e8. 2021. View Article : Google Scholar : PubMed/NCBI